CHMP adopts positive opinion of Opdivo in NSCLC and RCC
26 February 2016 | By Victoria White
Both indications are supported by Phase 3 studies in which Opdivo demonstrated a survival benefit versus a standard of care...
List view / Grid view
26 February 2016 | By Victoria White
Both indications are supported by Phase 3 studies in which Opdivo demonstrated a survival benefit versus a standard of care...
26 February 2016 | By Victoria White
Alprolix is a recombinant clotting factor therapy developed for haemophilia B by fusing factor IX to the Fc portion of immunoglobulin G subclass 1...
26 February 2016 | By Victoria White
Descovy is an investigational fixed-dose combination for the treatment of HIV-1 infection in adults and adolescents in combination with other HIV antiretroviral agents...
29 January 2016 | By Victoria White
Empliciti (elotuzumab) is an immunostimulatory antibody that specifically targets Signaling Lymphocyte Activation Molecule Family member 7 (SLAMF7), a cell-surface glycoprotein...
18 December 2015 | By Victoria White
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending the marketing authorisation of AstraZeneca’s Tagrisso (AZD9291, osimertinib) 80mg once-daily tablets for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small…
18 December 2015 | By Victoria White
The CHMP has adopted a positive opinion recommending the marketing authorisation of lesinurad 200mg tablets for the adjunctive treatment of hyperuricaemia in adult gout patients...
26 October 2015 | By Victoria White
If approved by the European Commission, Edurant will become available for the treatment of adolescents with HIV-1 for the first time...
23 October 2015 | By Victoria White
Cosentyx Phase III studies have consistently demonstrated significant improvements in the signs and symptoms of ankylosing spondylitis and psoriatic arthritis...
25 September 2015 | By Victoria White
The CHMP’s recommendation is based primarily on results of a Phase III study that showed that people who received the combination of Cotellic and Zelboraf lived over a year without their disease worsening...
25 September 2015 | By Victoria White
The CHMP’s recommendation will now be reviewed by the European Commission. If approved, Genvoya would be Gilead’s first single tablet regimen to contain TAF...
25 September 2015 | By Victoria White
Idarucizumab is intended for use in patients treated with dabigatran who require immediate anticoagulant reversal prior to urgent procedures or in case of uncontrolled bleeding...
25 September 2015 | By Victoria White
The CHMP adopted a positive opinion for an expanded indication of azacitidine for the treatment of adult patients aged 65 years or older with acute myeloid leukaemia who are not eligible for haematopoietic stem cell transplantation...
25 September 2015 | By Victoria White
The CHMP has adopted a positive opinion for Novartis’ Entresto (sacubitril/valsartan), marking an important milestone towards the drug becoming available in the EU.
30 July 2015 | By Victoria White
CHMP has granted a label extension for Synflorix to include protection against IPD caused by pneumococcal serotype 19A in children aged 6 weeks to 5 years...
28 July 2015 | By Victoria White
The CHMP has adopted a positive opinion for the marketing authorisation of Obizur for the treatment of bleeding episodes in patients with haemophilia...